{"id":17820,"date":"2022-06-30T18:48:40","date_gmt":"2022-06-30T13:18:40","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=17820"},"modified":"2022-06-30T18:48:43","modified_gmt":"2022-06-30T13:18:43","slug":"medtech-news-for-lumithera-3spine-teleflex","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex","title":{"rendered":"LumiThera\u2019s US LIGHTSITE III Trial; First Patient Enrolled in Vascular Closure Device Study of Teleflex; Varian\u2019s Flash Technology Clinical Trial, FAST-02; 3Spine\u2019s MOTUS Device; Illumina\u2019s Research Test to Detect Tumor Genome; Acutus Medical&#8217;s AcQCross Qx System"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fbbb852bed2\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fbbb852bed2\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex\/#LumiThera_Announced_the_Result_of_US_LIGHTSITE_III_Trial_of_Non-neovascular_Age-Related_Macular_Degeneration_AMD_Subjects_Treated_with_Photobiomodulation_PBM_using_the_Valeda%C2%AE_Light_Delivery_System\" >LumiThera Announced the Result of US LIGHTSITE III Trial of Non-neovascular Age-Related Macular Degeneration (AMD) Subjects Treated with Photobiomodulation (PBM) using the Valeda\u00ae Light Delivery System<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex\/#3Spine_Inc_Announced_IDE_Approval_for_MOTUS_device_the_implant_used_in_the_BalancedBack_Total_Joint_Replacement_Procedure\" >3Spine, Inc. Announced IDE Approval for MOTUS device, the implant used in the BalancedBack Total Joint Replacement Procedure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex\/#First_Patient_enrolled_in_vascular_closure_device_study_of_Teleflex\" >First Patient enrolled in vascular closure device study of Teleflex<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex\/#Illumina_Announced_the_Launch_of_Research_Test_Co-developed_with_Merck_used_to_Detect_Tumor_Genome_in_the_Patient\" >Illumina Announced the Launch of Research Test Co-developed with Merck used to Detect Tumor Genome in the Patient<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex\/#Investigational_Device_Exemption_IDE_Received_by_Varian_for_Flash_Technology_Clinical_Trial_FAST-02\" >Investigational Device Exemption (IDE) Received by Varian for Flash Technology Clinical Trial, FAST-02<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex\/#AcQCross_Qx_System_Launched_by_Acutus_Medical\" >AcQCross Qx System Launched by Acutus Medical<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-lumithera-announced-the-result-of-us-lightsite-iii-trial-of-non-neovascular-age-related-macular-degeneration-amd-subjects-treated-with-photobiomodulation-pbm-using-the-valeda-light-delivery-system\"><span class=\"ez-toc-section\" id=\"LumiThera_Announced_the_Result_of_US_LIGHTSITE_III_Trial_of_Non-neovascular_Age-Related_Macular_Degeneration_AMD_Subjects_Treated_with_Photobiomodulation_PBM_using_the_Valeda%C2%AE_Light_Delivery_System\"><\/span><strong>LumiThera Announced the Result of US LIGHTSITE III Trial of Non-neovascular Age-Related Macular Degeneration (AMD) Subjects Treated with Photobiomodulation (PBM) using the Valeda\u00ae Light Delivery System<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June 22, 2022, LumiThera Inc.,<\/strong> a commercial-stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, released the results of its <strong>US LIGHTSITE III multi-center clinical trial<\/strong> of <strong>non-neovascular (dry) age-related macular degeneration (AMD)<\/strong> patients treated with photobiomodulation (PBM) using the valeda\u00ae light delivery system.\u00a0<\/p>\n\n\n\n<p>The company conducted the trial at ten leading US retinal centers. LIGHTSITE III is a prospective, double-masked, randomized, multi-center clinical trial conducted with the aim to treat non-neovascular (dry) AMD subjects with PBM every four months for a duration of <strong>24 months.<\/strong> In the trial, <strong>100 patients<\/strong> were enrolled in a <strong>2:1 ratio <\/strong>of PBM to sham in the treatment groups.\u00a0<\/p>\n\n\n\n<p>The average age of patients in the trial was <strong>75 years<\/strong>, and the average duration of dry AMD from diagnosis was <strong>4.9 years<\/strong> prior to trial enrolment. The sham and PBM treatment groups had baseline best-corrected visual acuity (BCVA) letter values of <strong>69.4 + 0.8 and 70.1 + 0.7<\/strong>, respectively. The vast majority of individuals were diagnosed with moderate dry AMD. The study included 91 eyes in the PBM treatment group and <strong>54 eyes<\/strong> in the sham treatment group.<\/p>\n\n\n\n<p>The study results showed that the PBM treatment group outperformed the sham-treatment group in the prespecified primary outcome of BCVA at 13 months (<strong>p = 0.02<\/strong>). At the <strong>13-month time<\/strong> point, PBM-treated participants had a sustained, mean rise in ETDRS letter score of <strong>5.5 letters<\/strong> from baseline (<strong>p 0.0001<\/strong>) was observed. In the PBM therapy group, <strong>55%<\/strong> of individuals improved by more than 5 letters on the standard EDTRS eye chart, with a mean of <strong>9.7 letters<\/strong>, and 26% improved by more than 10 letters, with a mean of 12.8 letters.<\/p>\n\n\n\n<p>In naive individuals, the progression to later-stage disease pathology, such as the neovascular (wet) form or the development of Geographic Atrophy (GA), i.e., loss of retinal tissue, was examined. At month 13, the percentage conversion of dry AMD to wet AMD was <strong>1.8 percent<\/strong> for sham, 5.4 percent for PBM, and <strong>8.3 percent<\/strong> for non-study eye groups. At baseline, a few individuals exhibited GA <strong>(9 eyes at screening)<\/strong>, and they were evenly split across 5 PBM and 4 sham eyes. At month 13, <strong>6 more eyes <\/strong>had progressed, with new GA detected. At month 13, five of the <strong>55 sham eyes (9.1%) <\/strong>proceeded to new GA, whereas just one of the <strong>93 PBM eyes (1.1%)<\/strong> moved to new GA.<\/p>\n\n\n\n<p>Diana Do, MD, and Quan Dong Nguyen, MD, MSc, FARVO, Professors of Ophthalmology and members of the Retina Division at the Byers Eye Institute at Stanford University, a clinical site for the LIGHTSITE III trial said, <em>\u201cThe subjects had good starting vision with approximately 70% having between 20\/32 to 20\/40 visions. Study subjects were only enrolled in the study if their vision was 20\/32 to 20\/100 and no evidence of GA in the central macula.\u201d<\/em> They also added, <em>\u201cIntermediate dry AMD patients have pathology and visual impairment consistent with earlier stages in the disease and have not lost retinal tissue by progressing to GA. Thus there is an opportunity to improve their vision while retinal tissue is still viable. Therapy with PBM using the Valeda Light Delivery System may serve a significant unmet need for many of our patients with dry AMD who now have the potential to improve their visual acuity with treatment.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cOverall, the clinical results show improvements in vision; what is further interesting is the lack of drusen deposit in the PBM treated group, and potentially less patient conversions to wet form of disease,\u201d <\/em>remarked Glenn Jaffe, MD, Robert Machemer Professor of Ophthalmology; Chief, Vitreoretinal Division and Director, Duke Reading Center, the central imaging center for the LIGHTSITE III study.<em> <\/em>He also commented that <em>\u201cPatient progression to new GA was also evaluated and was less in the PBM group, and while the new GA progression numbers are small in this study group, all outcomes point in favour for PBM as a novel approach to treat dry AMD patients earlier in disease.\u201d<\/em><\/p>\n\n\n\n<p><em>Clark Tedford, PhD, President and CEO, LumiThera, said, \u201cThe study continues to strongly support that Valeda PBM treatments can improve visual acuity.\u201d He also added that, \u201cOur commercial and clinical trial experience has demonstrated an excellent safety and clinical benefit profile and we plan on submitting a PMA to the FDA for U.S. approval.\u201d<\/em><\/p>\n\n\n\n<p>Additionally, According to<strong> DelveInsight\u2019s <\/strong>&#8220;<a href=\"https:\/\/www.delveinsight.com\/report-store\/ophthalmic-devices-market\">Ophthalmic Devices Market<\/a>&#8221; report, the global ophthalmic device market was valued at <strong>USD 55.91 billion<\/strong> in 2021, growing at a <strong>CAGR of 4.12%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 71.23 billion<\/strong> by 2027. The rise in demand for ophthalmic devices is predominantly attributed due to the increasing prevalence of various eye-ailments such as <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/myopia-market\">myopia<\/a><\/strong>, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/glaucoma-market\">glaucoma<\/a><\/strong>, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-macular-degeneration-amd-market\">age-related macular degeneration<\/a><\/strong>, and others, the increasing burden of the geriatric patients, the increasing number of ophthalmic surgeries, and technological advancements in the product, that will increase the demand of the ophthalmic devices.<\/p>\n\n\n\n<p>As per the <strong>Delveinsight <\/strong>analysis, <strong>North America<\/strong> is expected to have a significant share in revenue in the overall ophthalmic market during the forecast period. This is due to the factors such as the increasing prevalence of ocular disorders, rising geriatric population, increasing prevalence of lifestyle disorders such as diabetes, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hypertension-pipeline-insight\">hypertension<\/a><\/strong>, and surging government programs to create awareness of eye-related disorders are expected to aid in the growth of North America in the ophthalmic device market.\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-3spine-inc-announced-ide-approval-for-motus-device-the-implant-used-in-the-balancedback-total-joint-replacement-procedure\"><span class=\"ez-toc-section\" id=\"3Spine_Inc_Announced_IDE_Approval_for_MOTUS_device_the_implant_used_in_the_BalancedBack_Total_Joint_Replacement_Procedure\"><\/span><strong>3Spine, Inc. Announced IDE Approval<\/strong> <strong>for<\/strong> <strong>MOTUS device, the implant used in the BalancedBack Total Joint Replacement Procedure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>June 22, 2022<\/strong>, <strong>3Spine, Inc., <\/strong>a medical device company developing a total joint replacement for the lumbar spine, announced <strong>FDA Investigational Device Exemption (IDE)<\/strong> approval for their US pivotal clinical trial.\u00a0<\/p>\n\n\n\n<p>The <strong>MOTUS device<\/strong> from <strong>3Spine<\/strong>, which is utilized in the BalancedBack Total Joint Replacement operation, is a &#8220;first of its kind&#8221; technology that replaces the function of the disc and facet joints via a posterior route. Through the restoration of the functional spinal unit, the surgery treats leg pain, back pain, and spinal instability while improving posture and restoring range of movement. <\/p>\n\n\n\n<p>In 2020, the <strong>Food and Drug Administration (FDA)<\/strong> classified <strong>MOTUS <\/strong>as a Breakthrough Device. The BalancedBack Total Joint Replacement is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment after decompression at one lumbar level from <strong>L1\/L2 to L5\/S1<\/strong> in skeletally mature patients with symptomatic lumbar degeneration with or without foraminal or recess spinal stenosis confirmed by radiographic imaging (CT, MRI, X-rays), with no more than a <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/spondylolisthesis-market-insights\">Grade 1 spondylolisthesis<\/a><\/strong> at the involved level. Prior to receiving the BalancedBack Total Joint Replacement, patients must have exhausted conservative (non-operative) treatment for at least 3 months (opioid use, physical therapy, invasive cortisone anti-inflammatory medications) or be determined to have a neurologic emergency or intractable pain.<\/p>\n\n\n\n<p><em>&#8220;This is important, breakthrough technology for an underserved patient population,&#8221;<\/em> said Justin Eggleton, Vice President of Spine Regulatory Affairs at MCRA. He also added, <em>&#8220;The considerations for such a novel treatment required significant resources at FDA, and we appreciate the agency&#8217;s dedication to the review. The FDA review team carefully and thoughtfully challenged over 10,000 pages of biomechanical data, clinical history, and an exhaustive battery of non-clinical testing. FDA&#8217;s review establishes an important foundation for our project. MCRA is excited to partner with 3Spine as CRO for the IDE to strengthen the safety and effectiveness profile for our future pre-market approval application.&#8221;<\/em><\/p>\n\n\n\n<p>Ron Yarbrough, Chief Operating Officer at 3Spine said, <em>&#8220;Breakthrough Device Designation was critical to our success in the IDE approval process,&#8221;<\/em> He also added that,<em> \u201cThis project is the culmination of decades of technical and clinical research in the lumbar spine, and while the courage of pioneering patients and surgeons brought us to this point, today it is all about the tenacity and expertise of the FDA review team. Our interactive review with FDA over the past two years has resulted in comprehensive coverage of an unparalleled number of technical disciplines, reflecting the potentially transformational nature of this spine technology. We are very excited to begin IDE enrollment.&#8221;<\/em><\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s &#8220;<a href=\"https:\/\/www.delveinsight.com\/report-store\/knee-reconstruction-devices-market\">Knee Reconstruction\/ Replacement Devices Market<\/a>&#8221; <\/strong>report, the global knee reconstruction of replacement devices market was valued at <strong>USD 7.87 billion<\/strong> in 2021, growing at a <strong>CAGR of 4.52%<\/strong> during the forecast period from 2022 to 2027 to reach <strong>USD 10.27 billion<\/strong> by 2027. The knee reconstruction devices market is slated to witness prosperity owing to factors such as the growing burgeoning old-age population and the rising prevalence of various knee-associated musculoskeletal disorders such as <a href=\"https:\/\/www.delveinsight.com\/blog\/knee-osteoarthritis-pipeline-therapies\">osteoarthritis<\/a>, <a href=\"https:\/\/www.delveinsight.com\/blog\/rheumatoid-arthritis-symptoms-causes-treatment-and-market-landscape\">rheumatoid arthritis<\/a>, and others. <\/p>\n\n\n\n<p>Furthermore, as per the <strong>Delveinsight analysis<\/strong>, among all regions, North America is estimated to hold the highest share in the global <a href=\"https:\/\/www.delveinsight.com\/report-store\/knee-reconstruction-devices-market\">knee replacement market<\/a> owing to the presence of advanced healthcare systems in the region along with an increase in healthcare spending in the region.\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-first-patient-enrolled-in-vascular-closure-device-study-of-teleflex\"><span class=\"ez-toc-section\" id=\"First_Patient_enrolled_in_vascular_closure_device_study_of_Teleflex\"><\/span><strong>First Patient enrolled in vascular closure device study of Teleflex<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> May 22, 2022, Teleflex Incorporated<\/strong>, a leading global provider of medical technologies, announced the first patient enrolment in a clinical study that is intended to demonstrate the safety of <strong>MANTA\u00ae Vascular Closure Device<\/strong> ultrasound (U\/S) guided closure, without dependence on the pre-procedural depth locator measurements.\u00a0<\/p>\n\n\n\n<p>The <strong>MANTA Ultra Study<\/strong> will enroll up to <strong>150 patients<\/strong> in up to <strong>15 investigational sites<\/strong> across the <strong>United States<\/strong> and <strong>Canada<\/strong>. The trial is a multi-center, single-arm trial employing the primary safety endpoint of any large bore access-site related <strong>Valve Academic Research Consortium-2 (VARC-2) <\/strong>Major Vascular Complication within 30 days (adapted from VARC-2 Criteria). The prevalence of access site problems has been linked to greater rates of morbidity and death, as well as higher expenses associated with extended lengths of stay. Ultrasound-guided access has been linked to a lower risk of major and small vascular problems, as well as a lower risk of life-threatening, major, and minor access site bleed issues.<\/p>\n\n\n\n<p>The goal of the study is to show that ultrasound enables precise deploy\u00a0and placement of the <strong>MANTA\u00ae Device<\/strong> anchor within the vessel. If successful, this strategy will allow the <strong>MANTA\u00ae Device<\/strong> to be employed in clinical circumstances where the baseline arterial depth is not determined or has altered intra- or post-operatively. The <strong>MANTA\u00ae Device ultrasound-guided closure<\/strong> is designed to provide an alternate solution to the traditional pre-procedural depth locator measuring procedure, giving operators more procedural freedom.<\/p>\n\n\n\n<p>In addition to the primary safety endpoint, the study will employ a secondary endpoint of any large bore access-site related VARC-2 minor vascular complication within 30 days (adapted from VARC-2 Criteria) and secondary effectiveness endpoints that include time to hemostasis, technical success, ambulation success, time to ambulation, treatment success and procedure time \u2013 all with 30-day and 12-month follow-up time points.<\/p>\n\n\n\n<p>Chris Buller, MD, Teleflex Medical Director, said <em>\u201cThe resourcing of the MANTA Ultra Study by Teleflex reflects our commitment to providing interventional cardiologists and surgeons with category-defining tools that enable difficult procedures and minimize complications \u2013 in this case, the complications attributable to large bore access that are inherent to TAVI procedures,\u201d<\/em><\/p>\n\n\n\n<p id=\"h-according-to-delveinsight-s-vascular-closure-devices-market-insights-competitive-landscape-and-market-forecast-2027-the-global-vascular-closure-devices-market-was-valued-at-usd-1-11-billion-in-2021-growing-at-a-cagr-of-6-18-during-the-forecast-period-from-2022-to-2027-to-reach-usd-1-59-billion-by-2027-the-vascular-closure-devices-is-slated-to-witness-prosperity-owing-to-factors-such-as-the-growing-prevalence-of-cardiovascular-diseases-which-can-be-further-attributed-to-the-increase-in-the-geriatric-population-wherein-aging-is-considered-to-have-a-deleterious-effect-on-blood-vessels-growing-prevalence-of-lifestyle-disorders-such-as-hypertension-diabetes-and-obesity-further-as-per-the-delveinsight-analysis-among-all-regions-north-america-is-estimated-to-hold-the-highest-share-in-the-global-cardiovascular-disorders-market-due-to-a-large-patient-pool-of-cardiovascular-disease-in-the-region\">According to <strong>DelveInsight\u2019s &#8220;<a href=\"https:\/\/www.delveinsight.com\/report-store\/vascular-closure-devices-market\">Vascular Closure Devices Market<\/a>\u201d<\/strong>, the global vascular closure devices market was valued at <strong>USD 1.11 billion <\/strong>in 2021, growing at a <strong>CAGR of 6.18%<\/strong> during the forecast period<strong> <\/strong>from 2022 to 2027 to reach <strong>USD 1.59 billion <\/strong>by 2027. The vascular closure devices is slated to witness prosperity owing to factors such as the growing prevalence of cardiovascular diseases which can be further attributed to the increase in the geriatric population wherein aging is considered to have a deleterious effect on blood vessels, growing prevalence of lifestyle disorders such as hypertension, diabetes, and obesity. <\/p>\n\n\n\n<p id=\"h-according-to-delveinsight-s-vascular-closure-devices-market-insights-competitive-landscape-and-market-forecast-2027-the-global-vascular-closure-devices-market-was-valued-at-usd-1-11-billion-in-2021-growing-at-a-cagr-of-6-18-during-the-forecast-period-from-2022-to-2027-to-reach-usd-1-59-billion-by-2027-the-vascular-closure-devices-is-slated-to-witness-prosperity-owing-to-factors-such-as-the-growing-prevalence-of-cardiovascular-diseases-which-can-be-further-attributed-to-the-increase-in-the-geriatric-population-wherein-aging-is-considered-to-have-a-deleterious-effect-on-blood-vessels-growing-prevalence-of-lifestyle-disorders-such-as-hypertension-diabetes-and-obesity-further-as-per-the-delveinsight-analysis-among-all-regions-north-america-is-estimated-to-hold-the-highest-share-in-the-global-cardiovascular-disorders-market-due-to-a-large-patient-pool-of-cardiovascular-disease-in-the-region\">Further, as per the Delveinsight analysis, among all regions, North America is estimated to hold the highest share in the global <a href=\"https:\/\/www.delveinsight.com\/blog\/upcoming-cardiovascular-drugs\">cardiovascular disorders market<\/a> due to a large patient pool of cardiovascular disease in the region.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-illumina-announced-the-launch-of-research-test-co-developed-with-merck-used-to-detect-tumor-genome-in-the-patient\"><span class=\"ez-toc-section\" id=\"Illumina_Announced_the_Launch_of_Research_Test_Co-developed_with_Merck_used_to_Detect_Tumor_Genome_in_the_Patient\"><\/span><strong>Illumina Announced the Launch of Research Test Co-developed with Merck used to Detect Tumor Genome in the Patient<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> May 22, 2022,<\/strong> <strong>Illumina, Inc.,<\/strong>\u00a0 a global leader in DNA sequencing and array-based technologies, announced the launch of a research test. The research test is co-developed with <strong>Merck<\/strong>. The research test builds upon a commitment to broadly enable comprehensive genomic profiling and enhance research critical to realizing precision medicine in oncology.\u00a0<\/p>\n\n\n\n<p>The <strong>TruSightTM Oncology 500<\/strong> assay, which is widely available, now includes an evaluation of a novel genetic signature. It will be available worldwide, with the exception of the United States and Japan, and will allow researchers to get deeper insights into the tumor genome by detecting genetic alterations employed in the assessment of homologous recombination insufficiency (HRD).<\/p>\n\n\n\n<p>The <strong>TruSight Oncology 500 HRD <\/strong>test is a next-generation sequencing (NGS)-based assay that combines the power of Illumina NGS technology with validated HRD technology from Myriad Genetics, allowing labs to detect genomic instability and analyze more than <strong>500 genes<\/strong> at the same time, including those relevant to HRD status. HRD is a genetic signature that describes when cells are unable to repair double-stranded DNA breaks properly. Cells rely on alternate, error-prone DNA repair processes when this happens, which can lead to genomic instability and, eventually, tumor development.<\/p>\n\n\n\n<p><em>&#8220;HRD status has emerged as an important biomarker in tumors that harbor high levels of DNA damage, such as ovarian, breast, prostate, and pancreatic cancers,&#8221; <\/em>said Phil Febbo, MD, chief medical officer at Illumina. He also added,<em> &#8220;With one sample and one test, TruSight Oncology 500 HRD assay provides labs with comprehensive, accurate, sensitive results that can greatly enhance our understanding of the genomic nature of a tumor.&#8221;<\/em><\/p>\n\n\n\n<p>Large-cohort studies show that comprehensive genomic profiling (CGP) has the potential to identify relevant genetic alterations in up to 90% of samples. A single, comprehensive assay to assess a wide range of biomarkers uses less sample and returns results more quickly compared to multiple, iterative tests. As a kitted, distributable solution, this test helps to remove barriers to the internalization of CGP and HRD testing, so that labs of all sizes can offer this powerful test.<\/p>\n\n\n\n<p><em>&#8220;We are pleased to reach this first milestone with Illumina to commercialize an assay for HRD assessment that will aid in advancing clinical research and broaden access to clinical trials,&#8221;<\/em> said Dr. Eric H. Rubin, senior vice president, early-stage development, clinical oncology, Merck Research Laboratories.<\/p>\n\n\n\n<p>According to <strong>DelveInsight\u2019s<\/strong> <strong>\u2018<a href=\"https:\/\/www.delveinsight.com\/report-store\/cancer-diagnostic-market\">Cancer Diagnostic Market<\/a>\u201d<\/strong> report, the global cancer diagnostic market is expected to grow at a <strong>9.43% CAGR<\/strong> during the forecast period (2022-2027). The increase in cancer diagnosis is predominantly owing to the increasing number of cases of cancer worldwide. <\/p>\n\n\n\n<p>Additionally, as per DelveInsight analysis, in the product type segment, the reagents and kits are expected to hold a considerable market share in the year 2021. This is due to the wide availability of reagents and kits in the detection of cancer, cell signaling, cell proliferation and viability, tumor suppressor gene, bioactive proteins, and other cancer cells.\u00a0<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investigational-device-exemption-ide-received-by-varian-for-flash-technology-clinical-trial-fast-02\"><span class=\"ez-toc-section\" id=\"Investigational_Device_Exemption_IDE_Received_by_Varian_for_Flash_Technology_Clinical_Trial_FAST-02\"><\/span><strong>Investigational Device Exemption (IDE) Received by Varian for Flash Technology Clinical Trial, FAST-02<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>On May 27, 2022, Varian, a Siemens Healthineers company<\/strong>, announced that the <strong>U.S. Food and Drug Administration (FDA) <\/strong>granted an Investigational Device Exemption (IDE) to advance Varian&#8217;s Flash clinical research program with the <strong>FAST-02 <\/strong>(FeAsibility Study of Flash therapy for the Treatment of Symptomatic Bone Metastases) clinical trial.<\/p>\n\n\n\n<p>Data from <strong>FAST-01<\/strong>, Flash&#8217;s first human clinical trial, was used to support the approval of the FAST-02 study, which will be published later this year.\u00a0<\/p>\n\n\n\n<p>The <strong>FAST-02 clinical study<\/strong> will cover bone metastases in the chest, expanding on the clinical data from FAST-01 and offering vital insights into the therapeutic usage of Flash therapy for cancer metastases. FAST-02 is scheduled to enroll 10 patients with painful thoracic bone metastases and will analyze treatment-related side effects and effectiveness using study participants&#8217; reported pain alleviation.<\/p>\n\n\n\n<p>Similar to FAST-01, FAST-02 was designed with input from leading scientific experts from the <strong>FlashForward&#x2122; Consortium<\/strong>.<\/p>\n\n\n\n<p>The <strong>Varian ProBeam\u00ae system&#8217;s<\/strong> proton particle accelerator has been adapted to provide Flash therapy in association with the FAST-02 clinical study, and Varian&#8217;s EclipseTM treatment planning system has also been changed to produce plans for the Flash treatments. Varian is the industry&#8217;s sole partner advancing the development of Flash therapy as an integrated, end-to-end solution that incorporates advancements in treatment planning, quality assurance, and therapy delivery technologies. Flash therapy, an experimental treatment modality delivering radiation therapy at ultra-high dose rates in typically less than one second, maybe over 100 times faster compared to conventional radiation therapy.<\/p>\n\n\n\n<p><em>&#8220;For the last decade, radiation oncologists have been exploring Flash therapy as an important opportunity to create a paradigm shift in the way we treat patients,&#8221;<\/em> said Breneman, Medical Director of the Cincinnati Children&#8217;s\/UC Health Proton Therapy Center, University of Cincinnati Cancer Center member. He also added, <em>&#8220;The FAST-01 trial laid the groundwork for the approval of FAST-02, and we are excited to continue the clinical research and evaluate Flash therapy in a new patient cohort.&#8221;<\/em><\/p>\n\n\n\n<p>Agam Sharda, Vice President of Flash Solutions at Varian, said, &#8220;<em>Receiving IDE approval for FAST-02 reaffirms our confidence in the potential of Flash therapy and represents an important step toward delivering this groundbreaking therapy in a clinical setting,&#8221;<\/em> He also added that, <em>&#8220;Together with our FlashForward Consortium, we have expanded Flash therapy research using our systems as we work to improve the patient experience. We look forward to continuing to collaborate with experts around the world to push the boundaries of innovation in cancer care.&#8221;<\/em><\/p>\n\n\n\n<p><em>&#8220;Preclinical research of Flash therapy indicates using ultra-high dose rates may be less toxic to patients overall and enhances sparing of adjacent healthy tissue,&#8221;<\/em> said Deepak &#8220;Dee&#8221; Khuntia, M.D., Senior Vice President and Chief Medical Officer of Varian. <em>&#8220;The FAST-02 study will advance our work toward an important proof of concept, particularly in deep-seated tumors. We are eager to build on our clinical understanding of Flash therapy as we continue our work to transform cancer care.&#8221;<\/em><\/p>\n\n\n\n<p>According to the <strong>DelveInsight <\/strong>analysis, the market for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/cancer-therapy-market\">Cancer Therapy Devices<\/a><\/strong> is anticipated to grow at a significant rate during the forecast period (2022-2027). This is owing to an increase in the prevalence of cancer globally. For instance, the <strong>GLOBOCAN<\/strong> study conducted by the <strong>International Agency for Research on Cancer <\/strong>mentioned that in the year 2020 there were an estimated number of <strong>19.3 million new cases of cancer<\/strong>, and approximately <strong>10.0 million cancer deaths<\/strong> were reported globally.\u00a0 The increasing prevalence of cancer will increase the <a href=\"https:\/\/www.delveinsight.com\/report-store\/cancer-therapy-market\">demand for cancer therapy<\/a> in the market, thereby owing to an increase in the overall market growth of the cancer therapy device in the market in the forecast period of 2022 \u2013 2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-acqcross-qx-system-launched-by-acutus-medical\"><span class=\"ez-toc-section\" id=\"AcQCross_Qx_System_Launched_by_Acutus_Medical\"><\/span><strong>AcQCross Qx System Launched by Acutus Medical<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> June27, 2022, <\/strong>Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, launched <strong>AcQCross&#x2122; Qx system<\/strong> for use with the <strong>TruSeal (TM) and FXD(TM) delivery system<\/strong> for the <strong>Watchman&#x2122; LAAC Device<\/strong>.\u00a0<\/p>\n\n\n\n<p>Gaining access to the left atrium requires physicians to cross the septum, a multi-step process that often involves the exchange of wires and needles while trying to achieve the proper angle and location on the septum. To decrease these exchanges, <strong>AcQCross <\/strong>is the first and only transseptal device designed with an integrated needle and dilator. Acutus may now provide sheath-compatible transseptal access devices for <strong>409,000 electrophysiological and structural cardiac treatments<\/strong> in the <strong>United States<\/strong>.<\/p>\n\n\n\n<p>AcQCross catheters are length-, diameter-, and tip-matched and engineered to lock onto the hub of market-leading sheaths used in the great majority of left-heart surgeries, including Watchman delivery. AcQCross may now be used with any sheath for practically every left-heart access operation, thanks to the increased product portfolio.<\/p>\n\n\n\n<p><em>\u201cCrossing the septum at the proper location is important when doing any left-sided heart procedure, but it can be especially critical to the success of delivering Watchman to the left atrial appendage,\u201d<\/em> said Dr. Tom Waggoner, DO, FACC, FSCAI, FSVM, RPVI, Director, Structural Heart Program and Cardiovascular Research, Tucson Medical Center, Tucson, Arizona. He added, <em>\u201cWith AcQCross, I can easily reposition without withdrawing or exchanging needles or wires, so its new compatibility with Watchman has made my procedures much safer for my patients and far more efficient for me and my team.\u201d<\/em><\/p>\n\n\n\n<p>David Roman, interim Chief Executive Officer, and Chief Financial Officer, Acutus Medical, said, <em>\u201cThe AcQCross system provides interventional cardiologists and electrophysiologists with unique benefits of broad compatibility with market-leading access sheaths while also enhancing procedure versatility and workflow,.\u201d<\/em> David Roman also said that <em>\u201cThe expanded AcQCross product line allows us to bring this innovative technology to a wider range of procedure categories that should drive sustained growth in this portfolio.\u201d<\/em><\/p>\n\n\n\n<p>According to<strong> DelveInsight\u2019s &#8220;<a href=\"https:\/\/www.delveinsight.com\/report-store\/cardiac-assist-devices-market\">Cardiac Assist Devices Market<\/a>&#8221; <\/strong>report,  the global cardiac assist devices market was valued at <strong>USD 2.89 billion<\/strong> in 2021, growing at a <strong>CAGR of 13.70%<\/strong> during the forecast period from 2022 to 2027, to reach<strong> USD 6.23 billion<\/strong> by 2027. The demand for cardiac assist devices is primarily motivated by the increasing prevalence of cardiovascular disorders, the number of geriatric patients, growth in new devices, increasing acceptance and penetration of assisting devices, and technological advancement in the product. <\/p>\n\n\n\n<p>As per the <strong>Delveinsight analysis<\/strong>, in the product type segment of the cardiac assist devices market, the ventricular assisting device accounts for the highest contributor to the cardiac assist devices market, due to the higher <a href=\"https:\/\/www.delveinsight.com\/report-store\/left-ventricular-dysfunction-epidemiology-forecast\">prevalence of ventricular failure<\/a>. The rising number of geriatric patients, increasing unhealthy lifestyle, and the rising prevalence of obesity account for the rising demand for ventricular assisting devices, thereby propelling the overall market growth of cardiac assist devices in the forecast period (2022 \u2013 2027).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>LumiThera Announced the Result of US LIGHTSITE III Trial of Non-neovascular Age-Related Macular Degeneration (AMD) Subjects Treated with Photobiomodulation (PBM) using the Valeda\u00ae Light Delivery System On June 22, 2022, LumiThera Inc., a commercial-stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, released the results of its US LIGHTSITE III multi-center [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":17825,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[1299,2558,19355,19154,140,19466,19465,19460,19459,19243,19462,19461,19464,19463],"industry":[17226],"therapeutic_areas":[17242,17228,17244],"class_list":["post-17820","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-age-related-macular-degeneration","tag-amd","tag-cancer-diagnostic-market","tag-cancer-diagnostics","tag-cancer-therapy","tag-cardiac-assist-devices","tag-cardiac-assist-devices-market","tag-knee-reconstruction","tag-ophthalmic-devices","tag-ophthalmic-devices-market","tag-replacement-devices","tag-replacement-devices-market","tag-vascular-closure-devices","tag-vascular-closure-devices-market","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-oncology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News and Updates | LumiThera, 3Spine, Teleflex, Acutus Medical<\/title>\n<meta name=\"description\" content=\"LumiThera\u2019s US LIGHTSITE Trial; 3Spine\u2019s MOTUS Device; Teleflex&#039;s Vascular Closure Device Study; Acutus Medical&#039;s AcQCross Qx System; FAST-02\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News and Updates | LumiThera, 3Spine, Teleflex, Acutus Medical\" \/>\n<meta property=\"og:description\" content=\"LumiThera\u2019s US LIGHTSITE Trial; 3Spine\u2019s MOTUS Device; Teleflex&#039;s Vascular Closure Device Study; Acutus Medical&#039;s AcQCross Qx System; FAST-02\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-30T13:18:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-30T13:18:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/30184814\/MedTech-News-for-LumiThera-3Spine-and-Teleflex.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News and Updates | LumiThera, 3Spine, Teleflex, Acutus Medical","description":"LumiThera\u2019s US LIGHTSITE Trial; 3Spine\u2019s MOTUS Device; Teleflex's Vascular Closure Device Study; Acutus Medical's AcQCross Qx System; FAST-02","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex","og_locale":"en_US","og_type":"article","og_title":"MedTech News and Updates | LumiThera, 3Spine, Teleflex, Acutus Medical","og_description":"LumiThera\u2019s US LIGHTSITE Trial; 3Spine\u2019s MOTUS Device; Teleflex's Vascular Closure Device Study; Acutus Medical's AcQCross Qx System; FAST-02","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-06-30T13:18:40+00:00","article_modified_time":"2022-06-30T13:18:43+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/30184814\/MedTech-News-for-LumiThera-3Spine-and-Teleflex.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex","name":"MedTech News and Updates | LumiThera, 3Spine, Teleflex, Acutus Medical","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/30184814\/MedTech-News-for-LumiThera-3Spine-and-Teleflex.png","datePublished":"2022-06-30T13:18:40+00:00","dateModified":"2022-06-30T13:18:43+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"LumiThera\u2019s US LIGHTSITE Trial; 3Spine\u2019s MOTUS Device; Teleflex's Vascular Closure Device Study; Acutus Medical's AcQCross Qx System; FAST-02","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-lumithera-3spine-teleflex#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/30184814\/MedTech-News-for-LumiThera-3Spine-and-Teleflex.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/30184814\/MedTech-News-for-LumiThera-3Spine-and-Teleflex.png","width":772,"height":482,"caption":"MedTech News for LumiThera, 3Spine and Teleflex"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/30184814\/MedTech-News-for-LumiThera-3Spine-and-Teleflex-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Age-related\u00a0macular degeneration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AMD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Cancer Diagnostic Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Cancer diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">cancer therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Cardiac Assist Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Cardiac Assist Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Knee Reconstruction<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Ophthalmic Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Ophthalmic Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Replacement Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Replacement Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Vascular Closure Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Vascular Closure Devices Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Age-related\u00a0macular degeneration<\/span>","<span class=\"advgb-post-tax-term\">AMD<\/span>","<span class=\"advgb-post-tax-term\">Cancer Diagnostic Market<\/span>","<span class=\"advgb-post-tax-term\">Cancer diagnostics<\/span>","<span class=\"advgb-post-tax-term\">cancer therapy<\/span>","<span class=\"advgb-post-tax-term\">Cardiac Assist Devices<\/span>","<span class=\"advgb-post-tax-term\">Cardiac Assist Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Knee Reconstruction<\/span>","<span class=\"advgb-post-tax-term\">Ophthalmic Devices<\/span>","<span class=\"advgb-post-tax-term\">Ophthalmic Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Replacement Devices<\/span>","<span class=\"advgb-post-tax-term\">Replacement Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Vascular Closure Devices<\/span>","<span class=\"advgb-post-tax-term\">Vascular Closure Devices Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jun 30, 2022","modified":"Updated on Jun 30, 2022"},"absolute_dates_time":{"created":"Posted on Jun 30, 2022 6:48 pm","modified":"Updated on Jun 30, 2022 6:48 pm"},"featured_img_caption":"MedTech News for LumiThera, 3Spine and Teleflex","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=17820"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17820\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/17825"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=17820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=17820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=17820"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=17820"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=17820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}